Targeting Lewis Y (Ley) in Small Cell Lung Cancer with a Humanized Monoclonal Antibody, hu3S193: A Pilot Trial Testing Two Dose Levels

Cornell University, Итак, New York, United States
Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer (Impact Factor: 5.8). 11/2007; 2(10):947-52. DOI: 10.1097/JTO.0b013e3181560dcc
Source: PubMed

ABSTRACT Lewis Y (Le(y)) is a blood group antigen with robust expression on the surface of epithelial tumors, including small cell lung cancer (SCLC), making it a potential target for antibody-based immunotherapy. 3S193, an immunoglobulin G3 monoclonal antibody, has demonstrated superior specificity, affinity, and cytotoxicity over other anti-Le(y) antibodies. A phase I trial of humanized 3S193 (hu3S193) with dosing up to 40 mg/m2 demonstrated tumor targeting without serious toxicities or the development of human anti-human antibodies.
We tested the targeting and pharmacokinetics of hu3S193 in patients with SCLC. Eligibility required progressive SCLC treated with up to three previous chemotherapy regimens, measurable disease not previously irradiated, and tumor samples positive for 3S193 by immunohistochemistry. Patients received four weekly injections of hu3S193, five patients at 10 mg/m2 and five patients at 20 mg/m2. The first and fourth injections were radiolabeled with indium-111 for gamma camera imaging.
Of 40 patients screened, 25 of 34 (74%) assessable SCLC tumor samples were 3S193 positive by immunohistochemistry. Ten patients were treated with hu3S193; nine completed all four injections. All fluorodeoxyglucose (FDG)-avid lesions >2 cm were visualized on antibody single-photon emission computed tomography. Some lesions overlying vascular structures could not be visualized. No difference was noted in imaging or pharmacokinetics between the first and fourth injections. Toxicities included grade 2 urticaria (n = 1), grade 1 vomiting (n = 2), and grade 2 hypertension (n = 1) transiently after infusion at the higher dose.
Given the strong tumor targeting, particularly at the higher dose, the favorable toxicity profile, and the potential for immunomodulatory effects, hu3S193 warrants further investigation in SCLC.

Download full-text


Available from: Achim A Jungbluth, Jun 29, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: Investigation of safety, tolerability, pharmacokinetics, and anti-tumor activity of the Lewis Y-specific, fully humanized monoclonal antibody (mAb) IGN311 in patients with Lewis Y positive tumors in a Phase I clinical trial. Ex-perimental Design: Twelve patients (pts) were enrolled in an open-label, uncontrolled, dose escalating Phase I study. Three pts received 50 mg, three pts 100 mg and six pts 200 mg IGN311 by i.v. infusion on days 1 and 15. Blood samples were taken immediately before infusion, and 0.5, 4, 8, 24 hours post infusion, as well as on days 3, 5 and 8 after the first and second infusion, respectively, and day 29. A final visit was scheduled for day 43. Results: No drug related adverse events were observed in the 50 mg and 100 mg dose groups. Three out of six patients in the 200 mg dose group showed drug related adverse reactions with nausea, vomiting and hypotension in one patient (NCI CTC grade 3) being the dose limiting toxicities. t 1/2 of IGN311 was ~20 days after second infusion of IGN311. Sera of patients receiving IGN311 were capable of lysing Lewis Y positive tumor cells in vitro by both, complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC). Circulating tumor cells found in the peripheral blood in two out of twelve pts prior to treatment were reduced after treatment to below the quantification limit of the detection method. None of the patients showed an increase in the number of disseminated tumor cells during treatment period. Conclu-sions: The good safety and PK profile, the biological activity regarding CDC and ADCC mediated tumor cell lysis, and the elimination of circulating tumor cells warrant further clinical investigation of IGN311.
  • Source
    Journla of Immunotherapy 11/2004; 27(6). DOI:10.1097/00002371-200411000-00042 · 3.35 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Small cell lung cancer (SCLC) is an aggressive malignancy with a poor prognosis. It can be very sensitive to radiation and cytotoxic chemotherapy and is potentially curable if all sites of disease can be encompassed in a radiation field. For the vast majority of patients relapse is the norm, with only limited gains from further lines of chemotherapy. In spite of the recognition of a number of molecular targets based on preclinical studies, targeted therapy for small cell lung cancer has yet to demonstrate any significant clinical benefit. This review summarizes the various targeted pharmacological approaches employed with a view to extending survival in extensive stage SCLC or improving on remission induction in limited stage disease. Pharmacological agents have targeted aberrant signal transduction pathways, proteins involved in cell cycle progression, apoptosis and angiogenesis. Additionally, immunomodulatory approaches have been used to stimulate an immune response against tumor associated antigens. Though the clinical data thus far is discouraging, drugs are still undergoing evaluation and more targets continue to be identified. There is considerable scope for further research and in particular combining newer therapies with existing treatment modalities to improve outcomes.
    Targeted Oncology 07/2008; 3(3):205-215. DOI:10.1007/s11523-008-0086-5 · 3.46 Impact Factor